| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
5,10,15,20-Tetrakis(4-hydroxyphenyl)porphyrin is a photosensitizer used in photodynamic therapy (PDT). Upon light activation, the compound generates reactive oxygen species that can destroy cancer cells. Porphyrin metal complexes are also important in vivo as they are included in chlorophyll for photosynthesis and in heme for oxygen transport in blood.
|
|---|---|
| ln Vitro |
In vitro, 5,10,15,20-Tetrakis(4-hydroxyphenyl)porphyrin is used as a photosensitizer due to its strong light absorption properties. It can absorb light energy and transfer electrons or energy. The compound has sharp absorptions around 400-500 nm and Q band absorptions around 500-700 nm. It is widely utilized in research focused on photodynamic therapy (PDT) for treating certain cancers.
|
| ln Vivo |
In vivo, 5,10,15,20-Tetrakis(4-hydroxyphenyl)porphyrin is effective in photodynamic therapy (PDT) for treating certain cancers by generating reactive oxygen species when exposed to light, helping to destroy cancer cells. Porphyrin metal complexes are important in vivo because they are included in chlorophyll for photosynthesis and in heme for oxygen transport in blood.
|
| Enzyme Assay |
For in vitro photosensitizer assays, 5,10,15,20-Tetrakis(4-hydroxyphenyl)porphyrin is evaluated for its ability to generate reactive oxygen species upon light activation. The compound is dissolved in DMSO or appropriate solvent and diluted in buffer. Cells or cell-free systems are treated with the compound and exposed to light at specific wavelengths (typically 400-500 nm). ROS generation is measured using fluorescent probes such as DCFH-DA.
|
| Cell Assay |
For in vitro cell-based experiments, 5,10,15,20-Tetrakis(4-hydroxyphenyl)porphyrin is evaluated for phototoxicity against cancer cell lines. Cells are seeded in 96-well plates and treated with the compound at various concentrations (typically 0.1-10 μM) for 2-24 hours, then exposed to light at appropriate wavelengths. Cell viability is assessed using MTT or resazurin-based assays. Dark toxicity controls are included to ensure light-dependent activity.
|
| Animal Protocol |
For in vivo animal studies, 5,10,15,20-Tetrakis(4-hydroxyphenyl)porphyrin is evaluated in mouse xenograft models of cancer for photodynamic therapy efficacy. Tumor-bearing mice are administered the compound via intravenous injection, and after a defined drug-light interval, the tumor area is exposed to light at specific wavelengths. Tumor volume is measured over time to assess treatment efficacy. Biodistribution and pharmacokinetic studies may also be conducted.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 5,10,15,20-Tetrakis(4-hydroxyphenyl)porphyrin are characterized in the context of photodynamic therapy. The compound has a molecular weight of 678.75 g/mol and is administered intravenously for PDT applications. It has strong light absorption properties and accumulates in tumor tissues. The compound is a solid at room temperature and should be stored at room temperature below 15°C in a cool, dark place.
|
| Toxicity/Toxicokinetics |
5,10,15,20-Tetrakis(4-hydroxyphenyl)porphyrin is a research chemical and should be handled with appropriate laboratory safety precautions. As a porphyrin, it may pose risks of skin and eye irritation. The compound is light-sensitive and should be protected from light. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a well-ventilated area.
|
| Additional Infomation |
5,10,15,20-Tetrakis(4-hydroxyphenyl)porphyrin (CAS 51094-17-8) is primarily a research-grade photosensitizer, not an FDA-approved pharmaceutical drug. Its primary applications are in photodynamic therapy (PDT) research for treating certain cancers by generating reactive oxygen species when exposed to light. The compound is widely used as a photosensitizer due to its strong light absorption properties. Porphyrin metal complexes are important in vivo as they are included in chlorophyll and heme. No clinical trials or approved indications exist for this compound as a drug.
|
| Molecular Formula |
C44H30N4O4
|
|---|---|
| Molecular Weight |
678.73
|
| Exact Mass |
678.226
|
| CAS # |
51094-17-8
|
| PubChem CID |
135438030
|
| Appearance |
Brown to black solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Melting Point |
>300ºC(lit.)
|
| Index of Refraction |
1.746
|
| LogP |
9.26
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
52
|
| Complexity |
973
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C1C([H])=C([H])C(=C([H])C=1[H])C1C2C([H])=C([H])C(=C(C3C([H])=C([H])C(=C([H])C=3[H])O[H])C3=C([H])C([H])=C(C(C4C([H])=C([H])C(=C([H])C=4[H])O[H])=C4C([H])=C([H])C(C(C5C([H])=C([H])C(=C([H])C=5[H])O[H])=C5C([H])=C([H])C=1N5[H])=N4)N3[H])N=2 |c:19,79,t:53,73|
|
| InChi Key |
VFHDWGAEEDVVPD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C44H30N4O4/c49-29-9-1-25(2-10-29)41-33-17-19-35(45-33)42(26-3-11-30(50)12-4-26)37-21-23-39(47-37)44(28-7-15-32(52)16-8-28)40-24-22-38(48-40)43(36-20-18-34(41)46-36)27-5-13-31(51)14-6-27/h1-24,45,48-52H
|
| Chemical Name |
4-[10,15,20-tris(4-hydroxyphenyl)-21,23-dihydroporphyrin-5-yl]phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 10 mg/mL (14.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4733 mL | 7.3667 mL | 14.7334 mL | |
| 5 mM | 0.2947 mL | 1.4733 mL | 2.9467 mL | |
| 10 mM | 0.1473 mL | 0.7367 mL | 1.4733 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
